SCHEMBL4471167

SCHEMBL4471167

O=C(C[C@H](O)[C@H](O)COP(=O)(O)O)c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.42
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
EPHX2 P34913 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 1/20 0.40
PGD P52209 2/20 0.40
FDPS P14324 2/20 0.39
LMNA P02545 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CTNNB1 P35222 2/20 0.39
WNT3A P56704 2/20 0.39
GSK3B P49841 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478366 0.78 CES2 (0.48) GRM4CES2CES1EPHX2SMN1; SMN2
SCHEMBL27883402 0.71 LMNA (0.47) GRM4CES2CES1EPHX2SMN1; SMN2
SCHEMBL4036991 0.70 PTPRA (0.56) GRM4CES2CES1EPHX2SMN1; SMN2
SCHEMBL15511653 0.70 CES2 (0.53) GRM4CES2CES1SMN1; SMN2KMT2A
SCHEMBL29915595 0.70 ALDH1A1 (0.55) GRM4CES2CES1KMT2ALMNA
SCHEMBL7109048 0.70 ALDH1A1 (0.55) GRM4CES2CES1KMT2ALMNA
SCHEMBL29096165 0.68 CES2 (0.52) GRM4CES2CES1EPHX2SMN1; SMN2
Potassium Ion SCHEMBL3752467 0.68 CES2 (0.52) GRM4CES2CES1EPHX2SMN1; SMN2
SCHEMBL11003297 0.68 GSK3B (0.49) GRM4CES2CES1EPHX2SMN1; SMN2
SCHEMBL18341350 0.68 PGD (0.67) PGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056894-B2 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2006-06-06 US claimed
EP-1370139-A2 INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2003-12-17 EP claimed
US-20020132783-A1 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2002-09-19 US claimed
WO-2002059084-A2 INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2002-08-01 WO claimed
US-7504489-B2 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2009-03-17 US disclosed
US-7056894-B2 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2006-06-06 US disclosed
US-20060084616-A1 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2006-04-20 US disclosed
EP-1370139-A2 INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2003-12-17 EP disclosed
US-20020132783-A1 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2002-09-19 US disclosed
WO-2002059084-A2 INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132783-A1 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof CD38, ADPRS, NTPCR GRM4 4844/4885CES2 631/4885CES1 473/4885
US-20060084616-A1 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof CD38, ADPRS, NTPCR GRM4 4844/4885CES2 668/4885CES1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.